Ann: CAR-T collaboration with Carina Biotech, page-10

  1. 1,173 Posts.
    lightbulb Created with Sketch. 243
    The trouble with CHM is that is doesn't have any propriety technology. It licenses technology from others who also do the investigations. Because of this they can't really sell the technology of be a target of a takeover.
    Check out todays ann about a collaboration. My bet is that the ASX will pull them up on something that is not material. If you compare it to what we have with Carina you will see a detailed announcement documenting who pays for what and what the possible outcomes.
    Beware CHM and its empty promises and its sycophants. Try and understand the science.

 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
0.2¢
Change
0.000(0.00%)
Mkt cap ! $2.142M
Open High Low Value Volume
0.2¢ 0.2¢ 0.2¢ $3.704K 1.851M

Buyers (Bids)

No. Vol. Price($)
25 19990238 0.2¢
 

Sellers (Offers)

Price($) Vol. No.
0.3¢ 6130560 15
View Market Depth
Last trade - 14.58pm 23/06/2025 (20 minute delay) ?
1AD (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.